How will the OECD’s Modified Nexus Approach to innovator-friendly tax regimes such as the UK’s patent box affect the life sciences industry? LSIPR investigates.
Pharma company Gilead has been in the headlines since it launched its blockbuster drug Sovaldi with a hefty price tag. Less reported, however, are its numerous patent licensing deals that ensure wider access to medicines in the developing world. LSIPR spoke to Christina Carlson, senior counsel at Gilead Sciences, to find out more.
The English Court of Appeal has issued the latest ruling in the patent dispute between Warner-Lambert and Actavis concerning Lyrica (pregabalin), says Arty Rajendra of Rouse Legal.
To opt out or not, that is the question for patentees under the new Unified Patent Court system, say Paul England and Anja Lunze of Taylor Wessing, in the third installment of a regular column on the unitary patent and UPC.
LSIPR takes a look at what the Practical Law Life Sciences Forum, due to take place on June 25, has to offer.
For companies that are considering conducting patent litigation around the world, the EPO is a very useful forum for testing their strategy or opposition tactics at a relatively low cost. Hazel Ford and Leythem Wall of Finnegan, Henderson, Farabow, Garrett & Dunner describe the numerous advantages of the procedures available.
In the second instalment of a regular column on the unitary patent and Unified Patent Court by law firm Taylor Wessing, Paul England and Simon Cohen discuss how watching the new system will also mean monitoring the old one.
Some of the parties involved in the landmark patent case Biogen v Medeva met in London in February to discuss the dispute in front of an invited audience. Here is an overview of their memories and the lessons they learned.
Orphan medicinal products in Europe benefit from a range of incentives, but the greatest of these is the promise of receiving a ten-year period of true market exclusivity, says Trevor Cook of Wilmer Cutler Pickering Hale and Dorr.
Previously for LSIPR, Jane Wainwright of Potter Clarkson investigated the emergence of self-colliding patent filings in Europe and their relevance to the life sciences. As the European Patent Office begins to review this issue at the highest level, she revisits the concept and why it is now being reconsidered.